Results 231 to 240 of about 3,339,972 (325)

Global Prognostic Impact of Substance Use in Alcohol‐Associated Hepatitis

open access: yesAlcohol, Clinical and Experimental Research, Volume 50, Issue 11, November 2026.
Alcohol‐associated hepatitis (AH) carries high short‐term mortality, yet behavioral risk factors are not captured by current prognostic models. In this multinational cohort of 814 patients, active cannabis use independently predicted mortality after accounting for liver disease severity and transplantation as a competing‐risk.
Omar Albhaisi   +49 more
wiley   +1 more source

Role for Cannabinoid Receptors in Human Proximal Tubular Hypertrophy

open access: yesCellular Physiology and Biochemistry, 2011
K. Jenkin   +3 more
semanticscholar   +1 more source

From emergence to replacement: The evolution of 3‐methylmethcathinone (3‐MMC) and its substitutes in the Dutch drug market (2012–2024)

open access: yesAddiction, Volume 121, Issue 11, Page 3065-3074, November 2026.
Abstract Background and aims The market for new psychoactive substances (NPS) is highly dynamic, with hundreds of substances emerging on the European drug market in the last decade. 3‐methylmethcathinone (3‐MMC), a synthetic cathinone and isomer of mephedrone (4‐MMC), gained popularity in the Netherlands due to its psychostimulant effects and initial ...
Nadia Robert Petronella Wilhelmina Hutten   +4 more
wiley   +1 more source

Opioid withdrawal syndrome‐associated cognitive impairment: A narrative review

open access: yesThe American Journal on Addictions, Volume 35, Issue 6, Page 661-672, November 2026.
Abstract Background and Objectives Opioid withdrawal syndrome (OWS) comprises a transient constellation of subjective symptoms and objective signs expressed by brain and other organs. Although cognitive impairment is well documented in opioid use and addiction, little is known about cognitive impairment that may specifically accompany OWS.
Faizan Khan   +2 more
wiley   +1 more source

Proof‐of‐concept trial of PP‐01 for mitigating cannabis withdrawal syndrome in participants with cannabis use disorder

open access: yesThe American Journal on Addictions, Volume 35, Issue 6, Page 739-747, November 2026.
Abstract Background and Objectives Cannabis withdrawal symptoms can be severe and protracted, significantly impeding the ability to abstain from cannabis use, resulting in failed quit attempts and relapse. This clinical trial evaluated safety and efficacy of PP‐01, a novel dual‑mechanism of action, investigational agent, for mitigating cannabis ...
Ashley F. Slagle   +4 more
wiley   +1 more source

Covalent fluorescent probes for 2‐arachidonoylglycerol metabolic pathways

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 22, Page 6656-6662, November 2026.
Abstract Covalent fluorescent probes have emerged as versatile chemical tools to visualise active enzymes in complex biological systems. When tailored for specific applications, ranging from activity‐based protein profiling for drug development to high spatiotemporal resolution imaging of enzymatic activities, these probes provide unique insights into ...
Nick D. F. Puijmbroeck   +1 more
wiley   +1 more source

Diagnosis and Management of Nitazene Dependence in Sydney, Australia: A Case Series

open access: yesDrug and Alcohol Review, Volume 45, Issue 7, November 2026.
ABSTRACT Introduction Nitazenes are synthetic opioids with potent μ‐receptor activity. There are increasing reports of nitazene overdoses worldwide. We report on a case series of protonitazene and metonitazene dependence responding to high dose medication for the treatment of opioid dependence in both inpatient and outpatient settings.
Daniel Dutkiewicz   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy